Mutant p53 and genomic instability in a transgenic mouse model of breast cancer.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

13 citing papers in PubMed, 37 citations in OpenAlex.

1. Mdm2 and MdmX RING Domains Play Distinct Roles in the Regulation of p53 Responses: A Comparative Study of Mdm2 and MdmX RING Domains in U2OS Cells.International journal of molecular sciences · 2020
   Article
2. Essential role for centromeric factors following p53 loss and oncogenic transformation.Genes & development · 2017
   Article
3. Genomic profiling of murine mammary tumors identifies potential personalized drug targets for p53-deficient mammary cancers.Disease models & mechanisms · 2016
   Article
4. p53 mutants induce transcription of NF-κB2 in H1299 cells through CBP and STAT binding on the NF-κB2 promoter and gain of function activity.Archives of biochemistry and biophysics · 2012
   Article
5. The "two-faced" effects of reactive oxygen species and the lipid peroxidation product 4-hydroxynonenal in the hallmarks of cancer.Cancers · 2010
   Article
6. Animal models of breast cancer for the study of pathogenesis and therapeutic insights.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2009
   Review
7. Dissecting the role of p53 phosphorylation in homologous recombination provides new clues for gain-of-function mutants.Nucleic acids research · 2008
   Article
8. Epigenetic mechanisms affect mutant p53 transgene expression in WAP-mutp53 transgenic mice.Oncogene · 2005
   Article
9. Centrosome amplification and the origin of chromosomal instability in breast cancer.Journal of mammary gland biology and neoplasia · 2004
   Review
10. Genotoxic stress leads to centrosome amplification in breast cancer cell lines that have an inactive G1/S cell cycle checkpoint.Oncogene · 2004
    Article
11. Centrosome amplification and the development of cancer.Oncogene · 2002
    Review
12. Knockout and transgenic mice of Trp53: what have we learned about p53 in breast cancer?Breast cancer research : BCR · 2002
    Review
13. Mammary glands reconstituted with Neu/ErbB2 transformed HC11 cells provide a novel orthotopic tumor model for testing anti-cancer agents.Oncogene · 2001
    Article

Corrections and comments

• Commented on by
  Mouse models for breast cancer.2000

Authors and funding

2 authors at 1 institution in 1 country.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as